aspirin has been researched along with Brain Damage, Chronic in 16 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We explored the outcomes of restarting aspirin use on secondary stroke and mortality in patients with chronic stroke 4 weeks after suffering from a TBI episode in Taiwan." | 8.31 | Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan. ( Chien, WC; Chou, CL; Chung, CH; Fann, LY; Hsu, YH; Sun, CA; Tang, SE; Wu, CC, 2023) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 7.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "A temporary middle cerebral artery occlusion (tMCAO) model was used in 80 Wistar rats to evaluate whether a high dose of Aspirin (40 mg/kg) applied with different initiation time points after stroke onset (30 min, 3 h, 6 h, 12 h, 20 rats for each time group) and followed by repeated administration (1, 2 and 3 days) is neuroprotective." | 5.34 | Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. ( Berger, C; Grau, A; Schwab, S; Zheng, Z, 2007) |
| " We explored the outcomes of restarting aspirin use on secondary stroke and mortality in patients with chronic stroke 4 weeks after suffering from a TBI episode in Taiwan." | 4.31 | Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan. ( Chien, WC; Chou, CL; Chung, CH; Fann, LY; Hsu, YH; Sun, CA; Tang, SE; Wu, CC, 2023) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 3.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed." | 2.69 | Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. ( Alberts, MJ; Berdan, LG; Califf, RM; Deckers, J; Graffagnino, C; Granger, CB; Harrington, RA; Laskowitz, DT; Lincoff, AM; MacAulay, CM; Mahaffey, KW; Miller, JM; Simoons, ML; Sloan, MA; Topol, EJ, 1999) |
| " In addition, the discussion here reviews select acute ischemic stroke intravenous thrombolytic studies, such as the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study and European Cooperative Acute Stroke Studies, select neuroprotectant and endovascular clot retrieval device studies, and large cooperative databases, such as the Virtual International Stroke Trials Archive and Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry, to explore relationships between baseline stroke severity and other possible factors associated with efficacy and safety outcomes." | 2.48 | How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials. ( Gorelick, PB, 2012) |
| "A temporary middle cerebral artery occlusion (tMCAO) model was used in 80 Wistar rats to evaluate whether a high dose of Aspirin (40 mg/kg) applied with different initiation time points after stroke onset (30 min, 3 h, 6 h, 12 h, 20 rats for each time group) and followed by repeated administration (1, 2 and 3 days) is neuroprotective." | 1.34 | Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. ( Berger, C; Grau, A; Schwab, S; Zheng, Z, 2007) |
| "It is concluded that the groups with alcohol abuse who used hepatotoxic drugs showed a picture of cortical changes (wide transport sulci and clear-cut or high-grade cortical changes) and also of subcortical aberrations, expressed as an increased widening of the third ventricle." | 1.28 | Computed tomography of the brain, hepatotoxic drugs and high alcohol consumption in male alcoholic patients and a random sample from the general male population. ( Mützell, S, 1992) |
| "The reasons given for treating fever were to make the child comfortable (99%), to prevent seizures (63%), and to satisfy parents (44%)." | 1.27 | House officer management of the febrile child. A survey. ( Herskowitz, L; Weiss, J, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, CL | 1 |
| Chung, CH | 1 |
| Hsu, YH | 1 |
| Wu, CC | 1 |
| Sun, CA | 1 |
| Chien, WC | 1 |
| Tang, SE | 1 |
| Fann, LY | 1 |
| Pullicino, PM | 1 |
| Thompson, JL | 1 |
| Sacco, RL | 1 |
| Sanford, AR | 1 |
| Qian, M | 1 |
| Teerlink, JR | 1 |
| Haddad, H | 1 |
| Diek, M | 1 |
| Freudenberger, RS | 1 |
| Labovitz, AJ | 1 |
| Di Tullio, MR | 1 |
| Lok, DJ | 1 |
| Ponikowski, P | 1 |
| Anker, SD | 1 |
| Graham, S | 1 |
| Mann, DL | 1 |
| Mohr, JP | 2 |
| Homma, S | 1 |
| Sanchez, J | 1 |
| Illnait, J | 1 |
| Mas, R | 1 |
| Mendoza, S | 1 |
| Fernandez, L | 1 |
| Mesa, M | 1 |
| Vega, H | 1 |
| Fernandez, J | 1 |
| Reyes, P | 1 |
| Ruiz, D | 1 |
| Wong, DK | 1 |
| Lurie, F | 1 |
| Wong, LL | 1 |
| Leroux, P | 1 |
| Hennebert, C | 1 |
| Catteau, J | 1 |
| Legros, H | 1 |
| Hennebert, O | 1 |
| Laudenbach, V | 1 |
| Marret, S | 1 |
| Gorelick, PB | 1 |
| Khalifeh, MR | 1 |
| Redett, RJ | 1 |
| Zheng, Z | 1 |
| Schwab, S | 1 |
| Grau, A | 1 |
| Berger, C | 1 |
| Weiss, J | 1 |
| Herskowitz, L | 1 |
| Pickard, JD | 1 |
| Walker, V | 1 |
| Brandt, L | 1 |
| Zygmunt, S | 1 |
| Smythe, J | 1 |
| Hartmann, A | 1 |
| Mahaffey, KW | 1 |
| Harrington, RA | 1 |
| Simoons, ML | 1 |
| Granger, CB | 1 |
| Graffagnino, C | 1 |
| Alberts, MJ | 1 |
| Laskowitz, DT | 1 |
| Miller, JM | 1 |
| Sloan, MA | 1 |
| Berdan, LG | 1 |
| MacAulay, CM | 1 |
| Lincoff, AM | 1 |
| Deckers, J | 1 |
| Topol, EJ | 1 |
| Califf, RM | 1 |
| Diener, HC | 1 |
| Mützell, S | 1 |
| Boyd, EM | 1 |
| Lipsmeyer, E | 1 |
| Ackerman, GL | 1 |
4 reviews available for aspirin and Brain Damage, Chronic
| Article | Year |
|---|---|
How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; | 2012 |
The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Damage, | 2006 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
Encephalopathy in toxicity tests on laboratory animals.
Topics: Animals; Aspirin; Atropine; Behavior, Animal; Brain Damage, Chronic; Brain Diseases; Caffeine; Casei | 1971 |
2 trials available for aspirin and Brain Damage, Chronic
| Article | Year |
|---|---|
[Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aspirin; Brain Damage, Chronic; Brain Ischemia; C | 2017 |
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Topics: Acute Disease; Age Factors; Aged; Angina, Unstable; Aspirin; Brain Damage, Chronic; Cerebral Hemorrh | 1999 |
10 other studies available for aspirin and Brain Damage, Chronic
| Article | Year |
|---|---|
Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan.
Topics: Adult; Aspirin; Brain Damage, Chronic; Brain Injuries, Traumatic; Drug Therapy, Combination; Female; | 2023 |
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; Heart Failure; | 2013 |
The effects of clopidogrel on elderly traumatic brain injured patients.
Topics: Aged; Aspirin; Brain Damage, Chronic; Brain Injuries; Cardiovascular Diseases; Case-Control Studies; | 2008 |
Neuroprotective effects vary across nonsteroidal antiinflammatory drugs in a mouse model of developing excitotoxic brain injury.
Topics: Acetaminophen; Adrenal Cortex Hormones; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Ste | 2010 |
Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin.
Topics: Acute Disease; Animals; Aspirin; Brain; Brain Damage, Chronic; Dose-Response Relationship, Drug; Dru | 2007 |
House officer management of the febrile child. A survey.
Topics: Acetaminophen; Aspirin; Brain Damage, Chronic; Fever; Humans; Infant; Seizures; Surveys and Question | 1983 |
Effect of intraventricular haemorrhage and rebleeding following subarachnoid haemorrhage on CSF eicosanoids.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Brain Damage, Chronic; Cerebral Ventricles; Dexamethasone; Di | 1994 |
Treatment of acute ischemic stroke: where are we?
Topics: Animals; Aspirin; Brain Damage, Chronic; Brain Ischemia; Calcium Channel Blockers; Cerebral Hemorrha | 1999 |
Computed tomography of the brain, hepatotoxic drugs and high alcohol consumption in male alcoholic patients and a random sample from the general male population.
Topics: Adult; Aged; Alcoholism; Analgesics; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Antipyrine; Aspiri | 1992 |
Irreversible brain damage after water intoxication.
Topics: Aged; Aspirin; Brain Damage, Chronic; Epilepsy, Tonic-Clonic; Female; Humans; Hypertonic Solutions; | 1966 |